U.S. Roadside Drug Testing Market Size, Share & Trends Analysis Report By Drug (Alcohol, Cannabis/Marijuana, Cocaine, Opioids, Amphetamine & Methamphetamine, LSD), By Sample, By Test Location, By States, And Segment Forecasts, 2024 - 2030
U.S. Roadside Drug Testing Market Size, Share & Trends Analysis Report By Drug (Alcohol, Cannabis/Marijuana, Cocaine, Opioids, Amphetamine & Methamphetamine, LSD), By Sample, By Test Location, By States, And Segment Forecasts, 2024 - 2030
U.S. Roadside Drug Testing Market Growth & Trends
The U.S. roadside drug testing market is anticipated to reach USD 1.62 billion by 2030 and is anticipated to expand at a CAGR of 4.71% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market for roadside drug testing in the U.S. is experiencing significant growth, driven by the increasing legalization of recreational cannabis and the rise in drug-impaired driving incidents. As states legalize marijuana, law enforcement agencies face new challenges in ensuring road safety. This has led to a surge in demand for advanced roadside drug testing devices that can quickly and accurately detect various substances.
Traditional methods like urine and blood tests are being supplemented by more efficient technologies, such as oral fluid testing, which is non-invasive and provides immediate results. One of the latest developments is the integration of artificial intelligence (AI) into these devices, enhancing their accuracy and reducing human error. Portable breathalyzers that can detect both alcohol and drugs are also becoming more prevalent. Additionally, there is ongoing research into devices that can measure impairment rather than just the presence of drugs, addressing the issue of varying tolerance levels among individuals.
Federal initiatives and funding are further bolstering this market, with the National Highway Traffic Safety Administration (NHTSA) and other agencies investing in the development of more sophisticated testing tools. As the U.S. continues to address the complexities of drug-impaired driving, the market for roadside drug testing is expected to expand, with innovations focusing on improving detection capabilities and ensuring the safety of all road users.
U.S. Roadside Drug Testing Market Report Highlights
The alcohol segment accounted for the largest revenue share in 2023. Alcohol testing remains dominant in the market due to the long-standing recognition of alcohol impairment as a significant safety concern, the presence of well-defined legal limits, and the widespread use of standardized devices like breathalyzers for accurate and reliable testing.
The breath segment captured the largest revenue share in 2023. Breath testing is the most commonly used method for detecting alcohol impairment because it is quick, non-invasive, and provides immediate results. Breathalyzers are portable, making them convenient for use by law enforcement officers during roadside checks.
The highway police segment held the largest revenue share in 2023. These officers are often the first responders at the scene of traffic stops, accidents, and roadside checks, where impaired driving is a significant concern.
Please note The report will be delivered in 2-3 business days upon order notification.
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug
1.2.2. Sample
1.2.3. Test Location
1.2.4. State scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug And Sample outlook
2.2.2. Test location outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. U.S. Roadside Drug Testing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increase in fatalities & accidents due to alcohol/substance abuse by drivers
3.2.1.2. Increased routine checking by police forces
3.2.1.3. Rapid growth in illicit substance consumption
3.2.2. Market restraint analysis
3.2.2.1. High cost of testing equipment
3.3. U.S. Roadside Drug Testing Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Opportunity Analysis
3.3.4. Roadside Drug Testing Spending Landscape, by State
3.3.5. Strategic Initiatives Landscape
3.3.6. Regulatory Landscape, by State Considering Current Competition
3.3.7. BY STATE, BY CITY, BY MUNICIPALITY
3.3.8. California
3.3.9. Texas
3.3.10. Florida
3.3.11. New York
3.3.12. Pennsylvania
3.3.13. Illinois
3.3.14. Ohio
3.3.15. Georgia
3.3.16. North Carolina
3.3.16.1. Penetration Index By State
3.3.16.2. Drug Influence Driving Statistics, By State
3.3.16.3. Dre Landscape And Statistics
3.3.16.4. Dre Training Statistics, 2018-2023
3.3.16.5. Number Of Dre By Category By State
3.3.16.6. Dre Qualitative Landscape By State
3.3.16.7. Case Studies, by State
Chapter 4. U.S. Roadside Drug Testing Market: Drug Estimates & Trend Analysis
4.1. U.S. Roadside Drug Testing Market: Drug Dashboard
4.2. U.S. Roadside Drug Testing Market: Drug Movement Analysis
4.3. U.S. Roadside Drug Testing Market by Drug, Revenue
4.4. Alcohol
4.4.1. Alcohol market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Cannabis/Marijuana
4.5.1. Cannabis/Marijuana market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Cocaine
4.6.1. Cocaine market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Opioids
4.7.1. Amphetamine & Methamphetamine market estimates and forecasts 2018 to 2030 (USD Million)
4.8. LSD
4.8.1. LSD market estimates and forecasts 2018 to 2030 (USD Million)
4.9. Others
4.9.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. U.S. Roadside Drug Testing Market: Sample Estimates & Trend Analysis
5.1. U.S. Roadside Drug Testing Market: Sample Dashboard
5.2. U.S. Roadside Drug Testing Market: Sample Movement Analysis
5.3. U.S. Roadside Drug Testing Market by Sample, Revenue
5.4. Saliva
5.4.1. Saliva market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Breath
5.5.1. Breath market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Urine
5.6.1. Urine market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Blood
5.7.1. Blood market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. U.S. Roadside Drug Testing Market: Test Location Estimates & Trend Analysis
6.1. U.S. Roadside Drug Testing Market: Test Location Dashboard
6.2. U.S. Roadside Drug Testing Market: Test Location Movement Analysis
6.3. U.S. Roadside Drug Testing Market by Test Location, Revenue
6.4. Highway Police
6.4.1. Highway Police market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Drug Enforcement Agencies
6.5.1. Drug enforcement agencies market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. U.S. Roadside Drug Testing Market: Regional Estimates & Trend Analysis by Drug, Sample, Test Location
7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. U.S.
7.4. Alabama
7.4.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.4.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.4.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.5. Alaska
7.5.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.5.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.5.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.6. Arizona
7.6.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.6.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.6.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.7. Arkansas
7.7.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.7.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.7.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.8. California
7.8.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.8.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.8.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.9. Colorado
7.9.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.9.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.9.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.10. Connecticut
7.10.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.10.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.10.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.11. Delaware
7.11.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.11.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.11.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.12. Florida
7.12.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.12.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.12.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.13. Georgia
7.13.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.13.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.13.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.14. Hawaii
7.14.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.14.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.14.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.15. Idaho
7.15.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.15.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.15.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.16. Illinois
7.16.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.16.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.16.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.17. Indiana
7.17.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.17.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.17.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.18. Iowa
7.18.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.18.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.18.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.19. Kansas
7.19.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.19.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.19.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.20. Kentucky
7.20.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.20.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.20.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.21. Louisiana
7.21.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.21.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.21.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.22. Maine
7.22.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.22.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.22.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.23. Maryland
7.23.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.23.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.23.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.24. Massachusetts
7.24.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.24.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.24.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.25. Michigan
7.25.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.25.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.25.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.26. Minnesota
7.26.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.26.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.26.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.27. Mississippi
7.27.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.27.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.27.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.28. Missouri
7.28.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.28.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.28.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.29. Montana
7.29.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.29.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.29.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.30. Nebraska
7.30.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.30.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.30.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.31. Nevada
7.31.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.31.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.31.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.32. New Hampshire
7.32.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.32.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.32.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.33. New Jersey
7.33.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.33.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.33.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.34. New Mexico
7.34.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.34.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.34.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.35. New York
7.35.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.35.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.35.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.36. North Carolina
7.36.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.36.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.36.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.37. North Dakota
7.37.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.37.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.37.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.38. Ohio
7.38.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.38.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.38.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.39. Oklahoma
7.39.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.39.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.39.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.40. Oregon
7.40.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.40.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.40.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.41. Pennsylvania
7.41.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.41.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.41.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.42. Rhode Island
7.42.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.42.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.42.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.43. South Carolina
7.43.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.43.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.43.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.44. South Dakota
7.44.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.44.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.44.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.45. Tennessee
7.45.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.45.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.45.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.46. Texas
7.46.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.46.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.46.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.47. Utah
7.47.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.47.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.47.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.48. Vermont
7.48.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.48.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.48.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.49. Virginia
7.49.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.49.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.49.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.50. Washington
7.50.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.50.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.50.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.51. West Virginia
7.51.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.51.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.51.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.52. Wisconsin
7.52.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.52.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.52.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.53. Wyoming
7.53.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.53.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.53.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners